LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors

James A. Allay, James E. Dennis, Stephen E. Haynesworth, Manas K. Majumdar, D. Wade Clapp, Leonard D. Shultz, Arnold I. Caplan, Stanton L. Gerson

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Human marrow-derived mesenchymal progenitor cells (hMPCs), which have the capacity for osteogenic and marrow stromal differentiation, were transduced with the myeloproliferative sarcoma virus (MPSV)-based retrovirus, vM5LacZ, that contains the LacZ and neo genes. Stable transduction and gene expression occurred in 18% of cells. After culture expansion and selection in G418, approximately 70% of neo hMPCs co-expressed LacZ. G418-selected hMPC retain their osteogenic potential and form bone in vivo when seeded into porous calcium phosphate ceramic cubes implanted subcutaneously into SCID mice. LacZ expression was evident within osteoblasts and osteocytes in bone developing within the ceramics 6 and 9 weeks after implantation. Likewise, hMPCs transduced with human interleukin-3 (hIL-3) cDNA, adhered to ceramic cubes and implanted into SCID mice, formed bone and secreted detectable levels of hIL-3 into the systemic circulation for at least 12 weeks. These data indicate that genetically transduced, culture-expanded bone marrow-derived hMPCs retain a precursor phenotype and maintain similar levels of transgene expression during osteogenic lineage commitment and differentiation in vivo. Because MPCs have been shown to differentiate into bone, cartilage, and tendon, these cells may be a useful target for gene therapy.

Original languageEnglish (US)
Pages (from-to)1417-1427
Number of pages11
JournalHuman Gene Therapy
Volume8
Issue number12
DOIs
StatePublished - Jan 1 1997

Fingerprint

Interleukin-3
Bone Marrow
Mesenchymal Stromal Cells
Ceramics
Bone and Bones
SCID Mice
Osteocytes
Lac Operon
Retroviridae
Osteoblasts
Transgenes
Sarcoma
Genetic Therapy
Tendons
Cartilage
Complementary DNA
Viruses
Phenotype
Gene Expression

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors. / Allay, James A.; Dennis, James E.; Haynesworth, Stephen E.; Majumdar, Manas K.; Wade Clapp, D.; Shultz, Leonard D.; Caplan, Arnold I.; Gerson, Stanton L.

In: Human Gene Therapy, Vol. 8, No. 12, 01.01.1997, p. 1417-1427.

Research output: Contribution to journalArticle

Allay, James A. ; Dennis, James E. ; Haynesworth, Stephen E. ; Majumdar, Manas K. ; Wade Clapp, D. ; Shultz, Leonard D. ; Caplan, Arnold I. ; Gerson, Stanton L. / LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors. In: Human Gene Therapy. 1997 ; Vol. 8, No. 12. pp. 1417-1427.
@article{59188812330f46bf8971b46012e0c5b3,
title = "LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors",
abstract = "Human marrow-derived mesenchymal progenitor cells (hMPCs), which have the capacity for osteogenic and marrow stromal differentiation, were transduced with the myeloproliferative sarcoma virus (MPSV)-based retrovirus, vM5LacZ, that contains the LacZ and neo genes. Stable transduction and gene expression occurred in 18{\%} of cells. After culture expansion and selection in G418, approximately 70{\%} of neo hMPCs co-expressed LacZ. G418-selected hMPC retain their osteogenic potential and form bone in vivo when seeded into porous calcium phosphate ceramic cubes implanted subcutaneously into SCID mice. LacZ expression was evident within osteoblasts and osteocytes in bone developing within the ceramics 6 and 9 weeks after implantation. Likewise, hMPCs transduced with human interleukin-3 (hIL-3) cDNA, adhered to ceramic cubes and implanted into SCID mice, formed bone and secreted detectable levels of hIL-3 into the systemic circulation for at least 12 weeks. These data indicate that genetically transduced, culture-expanded bone marrow-derived hMPCs retain a precursor phenotype and maintain similar levels of transgene expression during osteogenic lineage commitment and differentiation in vivo. Because MPCs have been shown to differentiate into bone, cartilage, and tendon, these cells may be a useful target for gene therapy.",
author = "Allay, {James A.} and Dennis, {James E.} and Haynesworth, {Stephen E.} and Majumdar, {Manas K.} and {Wade Clapp}, D. and Shultz, {Leonard D.} and Caplan, {Arnold I.} and Gerson, {Stanton L.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1089/hum.1997.8.12-1417",
language = "English (US)",
volume = "8",
pages = "1417--1427",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors

AU - Allay, James A.

AU - Dennis, James E.

AU - Haynesworth, Stephen E.

AU - Majumdar, Manas K.

AU - Wade Clapp, D.

AU - Shultz, Leonard D.

AU - Caplan, Arnold I.

AU - Gerson, Stanton L.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Human marrow-derived mesenchymal progenitor cells (hMPCs), which have the capacity for osteogenic and marrow stromal differentiation, were transduced with the myeloproliferative sarcoma virus (MPSV)-based retrovirus, vM5LacZ, that contains the LacZ and neo genes. Stable transduction and gene expression occurred in 18% of cells. After culture expansion and selection in G418, approximately 70% of neo hMPCs co-expressed LacZ. G418-selected hMPC retain their osteogenic potential and form bone in vivo when seeded into porous calcium phosphate ceramic cubes implanted subcutaneously into SCID mice. LacZ expression was evident within osteoblasts and osteocytes in bone developing within the ceramics 6 and 9 weeks after implantation. Likewise, hMPCs transduced with human interleukin-3 (hIL-3) cDNA, adhered to ceramic cubes and implanted into SCID mice, formed bone and secreted detectable levels of hIL-3 into the systemic circulation for at least 12 weeks. These data indicate that genetically transduced, culture-expanded bone marrow-derived hMPCs retain a precursor phenotype and maintain similar levels of transgene expression during osteogenic lineage commitment and differentiation in vivo. Because MPCs have been shown to differentiate into bone, cartilage, and tendon, these cells may be a useful target for gene therapy.

AB - Human marrow-derived mesenchymal progenitor cells (hMPCs), which have the capacity for osteogenic and marrow stromal differentiation, were transduced with the myeloproliferative sarcoma virus (MPSV)-based retrovirus, vM5LacZ, that contains the LacZ and neo genes. Stable transduction and gene expression occurred in 18% of cells. After culture expansion and selection in G418, approximately 70% of neo hMPCs co-expressed LacZ. G418-selected hMPC retain their osteogenic potential and form bone in vivo when seeded into porous calcium phosphate ceramic cubes implanted subcutaneously into SCID mice. LacZ expression was evident within osteoblasts and osteocytes in bone developing within the ceramics 6 and 9 weeks after implantation. Likewise, hMPCs transduced with human interleukin-3 (hIL-3) cDNA, adhered to ceramic cubes and implanted into SCID mice, formed bone and secreted detectable levels of hIL-3 into the systemic circulation for at least 12 weeks. These data indicate that genetically transduced, culture-expanded bone marrow-derived hMPCs retain a precursor phenotype and maintain similar levels of transgene expression during osteogenic lineage commitment and differentiation in vivo. Because MPCs have been shown to differentiate into bone, cartilage, and tendon, these cells may be a useful target for gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030823167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030823167&partnerID=8YFLogxK

U2 - 10.1089/hum.1997.8.12-1417

DO - 10.1089/hum.1997.8.12-1417

M3 - Article

C2 - 9287142

AN - SCOPUS:0030823167

VL - 8

SP - 1417

EP - 1427

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -